Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis (Q90307937)

From Wikidata

Jump to navigation Jump to search

scientific article published on 03 December 2018

Language	Label	Description	Also known as
English	Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis	scientific article published on 03 December 2018

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30521694 AND SRC:MED&resulttype=core&format=json

12 April 2020

0 references

Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30521694 AND SRC:MED&resulttype=core&format=json

12 April 2020

chronic obstructive pulmonary disease

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

author name string

Yuji Oba

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30521694 AND SRC:MED&resulttype=core&format=json

12 April 2020

Edna Keeney

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30521694 AND SRC:MED&resulttype=core&format=json

12 April 2020

Namratta Ghatehorde

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30521694 AND SRC:MED&resulttype=core&format=json

12 April 2020

Sofia Dias

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30521694 AND SRC:MED&resulttype=core&format=json

12 April 2020

publication date

3 December 2018

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30521694 AND SRC:MED&resulttype=core&format=json

12 April 2020

Cochrane Database of Systematic Reviews

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30521694 AND SRC:MED&resulttype=core&format=json

12 April 2020

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30521694 AND SRC:MED&resulttype=core&format=json

12 April 2020

CD012620

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30521694 AND SRC:MED&resulttype=core&format=json

12 April 2020

Quality of life changes in COPD patients treated with salmeterol

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measuring inconsistency in meta-analyses

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolerance to bronchodilating effects of salmeterol in COPD

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of registered and published primary outcomes in randomized controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Beclomethasone/formoterol in the management of COPD: a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and Efficacy of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler Compared with Fluticasone Propionate/Salmeterol Diskus in Patients with Chronic Obstructive Pulmonary Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

GRADE guidelines 6. Rating the quality of evidence—imprecision

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of budesonide/formoterol pMDI on COPD exacerbations: A double-blind, randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute effects of indacaterol on lung hyperinflation in moderate COPD: A comparison with tiotropium

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: Phase III study results

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of combination treatment on lung volumes and exercise endurance time in COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of trial sample size on treatment effect estimates: meta-epidemiological study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence synthesis for decision making 3: heterogeneity--subgroups, meta-regression, bias, and bias-adjustment

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tiotropium Respimat inhaler and the risk of death in COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26-week Asia-Pacific study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair(®) in chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pulmonary rehabilitation for chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tiotropium olodaterol shows clinically meaningful improvements in quality of life

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An Official American Thoracic Society/European Respiratory Society Policy Statement: Enhancing Implementation, Use, and Delivery of Pulmonary Rehabilitation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influenza vaccination in the elderly: why are the overall benefits still hotly debated?

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Compare the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-sev

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-acting beta2-agonists versus long-acting muscarinic antagonists in patients with stable COPD: A systematic review and meta-analysis of randomized controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluticasone propionate/formoterol for COPD management: a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30521694

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/14651858.CD012620.PUB2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30521694 AND SRC:MED&resulttype=core&format=json

12 April 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30521694 AND SRC:MED&resulttype=core&format=json

12 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30521694 AND SRC:MED&resulttype=core&format=json

12 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q90307937&oldid=2235097818"